https://www.pharmaradar360.com/article/864235e2c92b2b1ePharmaRadar360en2026-04-11T00:00:00.000ZTerms & Conditionshttps://www.pharmaradar360.com/article/9164e8a3ea4188d8PharmaRadar360en2026-04-11T00:00:00.000ZPharma Research & Developmenthttps://www.pharmaradar360.com/article/12b876500adab029PharmaRadar360en2026-04-11T00:00:00.000ZAgro R&Dhttps://www.pharmaradar360.com/article/7560e40c6587f273PharmaRadar360en2026-04-11T00:00:00.000Zresearch developmenthttps://www.pharmaradar360.com/article/17ab2695881ddde2PharmaRadar360en2026-04-11T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/a6d04440b8d67e7bPharmaRadar360en2026-04-11T00:00:00.000ZLatest Researchhttps://www.pharmaradar360.com/article/19f59684ccd74cc6PharmaRadar360en2026-04-11T00:00:00.000ZGeliose Mobility, an IIT Delhi incubated startup, launches ‘HOPE’, an affordable electric scooter for last mile delivery and personal commutehttps://www.pharmaradar360.com/article/2f248d6ce8bb4cebPharmaRadar360en2026-04-10T21:04:26.000ZAllogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 202https://www.pharmaradar360.com/article/98bd3f68fba7139fPharmaRadar360en2026-04-10T20:53:38.000ZPredicting T Cell Recognition: New Insights from Large-Scale Activation Datahttps://www.pharmaradar360.com/article/cd5efb6e2cb34c46PharmaRadar360en2026-04-10T20:00:36.000ZGAP Nail™ Endo-Exo Medullary Systemhttps://www.pharmaradar360.com/article/1ab8d0c52724348dPharmaRadar360en2026-04-10T16:00:13.000ZRegister medical devices to place on the markethttps://www.pharmaradar360.com/article/830b8ec3b42c913fPharmaRadar360en2026-04-10T16:00:00.000ZDecision: Advertising investigations: March 2026https://www.pharmaradar360.com/article/c66db7daf1cc0ecfPharmaRadar360en2026-04-10T16:00:00.000ZKennedy expands ACIP function, membership criteriahttps://www.pharmaradar360.com/article/5b715e12d81ebb52PharmaRadar360en2026-04-10T15:30:00.000Z日本新薬とイクスフォレストセラピューティクス RNA構造を標的とした創薬研究に関する契約を締結https://www.pharmaradar360.com/article/d9b6e6f4728831a0PharmaRadar360en2026-04-10T15:08:25.000ZVirtual Twins: What They Are & Their Impact in Life Scienceshttps://www.pharmaradar360.com/article/111274929215e1bbPharmaRadar360en2026-04-10T14:00:00.000ZMeeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 April 2026https://www.pharmaradar360.com/article/4d9ceb5c4c37ee01PharmaRadar360en2026-04-10T12:35:30.000ZeXoZymes CCO, Damien Perriman, outlines NCTx strategy and the commercial path for cell-free biomanufacturing on Grow Everything podcasthttps://www.pharmaradar360.com/article/7a216e651106fb9bPharmaRadar360en2026-04-10T12:29:45.000ZANMAT concluyó el proceso para la baja definitiva de las firmas HLB PHARMA GROUP S.A. y LABORATORIOS RAMALLO S.A.https://www.pharmaradar360.com/article/3c0f8e692dacdbe3PharmaRadar360en2026-04-10T10:00:00.000ZTislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002)https://www.pharmaradar360.com/article/8857248d0343ec2cPharmaRadar360en2026-04-10T08:45:56.000ZCENRIFKIhttps://www.pharmaradar360.com/article/e166fe404610756cPharmaRadar360en2026-04-10T08:00:00.000Z「デジタルトランスフォーメーション銘柄（DX銘柄）2026」選定のお知らせhttps://www.pharmaradar360.com/article/f926d17dcb34b0faPharmaRadar360en2026-04-10T08:00:00.000ZChugai Selected as “Digital Transformation Stocks (DX Stocks) 2026”https://www.pharmaradar360.com/article/4ffded644d4b86c0PharmaRadar360en2026-04-10T07:00:00.000ZA Clínic-IDIBAPS study discovers that nanoparticles with DNA enhance the effect of immunotherapy against cancerhttps://www.pharmaradar360.com/article/4d6a4308a4bc8473PharmaRadar360en2026-04-10T03:15:00.000ZDifferences in cells’ protein factories may help explain human diversityhttps://www.pharmaradar360.com/article/5a40dbb5cfb5094bPharmaRadar360en2026-04-10T03:00:00.000Z[SHINSA]Considerations for clinical development of intravenous formulations containing the same active ingredient as oral products for patients who are temporarily unable to receive oral administration in epilepsy treatment （Early consideration） postedhttps://www.pharmaradar360.com/article/9103b3a1cebe5467PharmaRadar360en2026-04-10T01:30:00.000ZAlexion data at 2026 AAN Annual Meeting reflects industry-leading portfolio and commitment to enhancing care across rare diseaseshttps://www.pharmaradar360.com/article/3dfd85876dbf074ePharmaRadar360en2026-04-10T01:15:26.000ZAnalysis of NPC1 Genotypes: Findings From the US Arimoclomol Expanded Access Program for Niemann-Pick Disease Type Chttps://www.pharmaradar360.com/article/09ccb62990dfe934PharmaRadar360en2026-04-10T01:00:00.000ZWhy do anglerfish have glowing lures? It might be sexhttps://www.pharmaradar360.com/article/bc4fcba9d4b99077PharmaRadar360en2026-04-10T00:00:00.000ZShionogi Selected as a “DX Stock 2026”https://www.pharmaradar360.com/article/23aacc01a6fc6a7dPharmaRadar360en2026-04-10T00:00:00.000ZOrion publishes Interim Report for January–March 2026 and holds a webcast on 23 April 20264/10/2026 Press releasehttps://www.pharmaradar360.com/article/590fdec1e8e3be5cPharmaRadar360en2026-04-10T00:00:00.000ZCD22-targeted immunotherapy for B-cell acute lymphoblastic leukemia progressing following CD19-targeted immunotherapyhttps://www.pharmaradar360.com/article/404d785b59a9a07aPharmaRadar360en2026-04-10T00:00:00.000ZTerminal T-cell exhaustion predicts tumor control independent of immunotherapy in ovarian cancerhttps://www.pharmaradar360.com/article/7cd148ff1e968ffbPharmaRadar360en2026-04-10T00:00:00.000ZSLC25A1 upregulation promotes HNSCC cisplatin resistance via H3K27ac-mediated cellular senescencehttps://www.pharmaradar360.com/article/85acba16356a96b3PharmaRadar360en2026-04-10T00:00:00.000ZDeepath-SCC: a deep learning model for accurate tissue origin identification in squamous cell carcinomahttps://www.pharmaradar360.com/article/6759d1b0dafb588fPharmaRadar360en2026-04-10T00:00:00.000ZOutcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 studyhttps://www.pharmaradar360.com/article/84391a5d68d16155PharmaRadar360en2026-04-10T00:00:00.000ZThe role of the molecular tumor board: learnings from the ROME trialhttps://www.pharmaradar360.com/article/d7022620a11be15fPharmaRadar360en2026-04-10T00:00:00.000ZDeep learning-based pathomics signature predicts prognosis and treatment response in gastric cancer: a multicenter retrospective studyhttps://www.pharmaradar360.com/article/3efcb6cb33119118PharmaRadar360en2026-04-10T00:00:00.000ZIdorsia | Media Releasehttps://www.pharmaradar360.com/article/5b600e5c7b1f3b48PharmaRadar360en2026-04-10T00:00:00.000ZIdorsia | News archivehttps://www.pharmaradar360.com/article/40f7e2112f470eb9PharmaRadar360en2026-04-10T00:00:00.000ZIdorsia issues invitation to the 2026 Annual General Meeting of Shareholdershttps://www.pharmaradar360.com/article/66c6879f5445e395PharmaRadar360en2026-04-10T00:00:00.000ZBehind the Science magazine | GSKhttps://www.pharmaradar360.com/article/2ac4b103cfe30425PharmaRadar360en2026-04-10T00:00:00.000ZApr 10,2026 | Chugai Selected as “Digital Transformation Stocks (DX Stocks) 2026” | News | CHUGAI PHARMACEUTICAL CO., LTD.https://www.pharmaradar360.com/article/8614361c7943f5cdPharmaRadar360en2026-04-10T00:00:00.000ZStroke Visionaries: Dr. Erika Weilhttps://www.pharmaradar360.com/article/b13297fc24783793PharmaRadar360en2026-04-10T00:00:00.000ZViatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meetinghttps://www.pharmaradar360.com/article/fe73c55896b51a4bPharmaRadar360en2026-04-10T00:00:00.000ZViking Therapeutics to Participate at Upcoming Investor Conferenceshttps://www.pharmaradar360.com/article/43bf7ad07ba58d2fPharmaRadar360en2026-04-10T00:00:00.000ZIDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026https://www.pharmaradar360.com/article/8c30626db2653a50PharmaRadar360en2026-04-10T00:00:00.000ZWHO releases US$800,000 from its Contingency Fund for Emergencies for Iran health responsehttps://www.pharmaradar360.com/article/8f76d885e6405a3aPharmaRadar360en2026-04-09T21:17:00.000ZFoundayo™ (orforglipron), la nueva pastilla GLP-1 de Lilly que se administra por vía oral para la pérdida de peso, ahora está disponible en Estados Unidos.https://www.pharmaradar360.com/article/0ef10a540d9626dcPharmaRadar360en2026-04-09T20:30:00.000ZCharles River Advances Cardiovascular Health Awareness Through Support of the American Heart Associationhttps://www.pharmaradar360.com/article/5fe49ef3eec8d9eePharmaRadar360en2026-04-09T20:25:00.000ZEmergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Programhttps://www.pharmaradar360.com/article/527e601285f51933PharmaRadar360en2026-04-09T20:15:00.000ZBD to Announce Financial Results for its Second Quarter of Fiscal 2026https://www.pharmaradar360.com/article/dbf6f692f558868dPharmaRadar360en2026-04-09T20:05:00.000ZRick Byrd to Retire from BDhttps://www.pharmaradar360.com/article/8265683cb62bb2d2PharmaRadar360en2026-04-09T19:45:26.000ZFrom Signal to Strategy: Using current, credible data for publication impact monitoring and continuous improvement planninghttps://www.pharmaradar360.com/article/5881c9c0e363ca51PharmaRadar360en2026-04-09T19:45:26.000ZFrom Signal to Strategy: Using current, credible data for publication impact monitoring and continuous improvement planninghttps://www.pharmaradar360.com/article/009813019b4001faPharmaRadar360en2026-04-09T18:25:23.000ZPPC Landing Page Template VHH Services V.2https://www.pharmaradar360.com/article/5486fe20c3d68906PharmaRadar360en2026-04-09T18:01:27.000ZUniversity College of London Hospitals NHS Trust (UCLH)https://www.pharmaradar360.com/article/9d41afe6edbeed52PharmaRadar360en2026-04-09T18:01:25.000ZCambridge University Hospitals NHS Foundation Trusthttps://www.pharmaradar360.com/article/4f30c0c42e06656ePharmaRadar360en2026-04-09T18:01:22.000ZManchester University NHS Foundation Trusthttps://www.pharmaradar360.com/article/14fac09106a2bdecPharmaRadar360en2026-04-09T18:01:17.000ZHôpital La Pitié Salpêtrièrehttps://www.pharmaradar360.com/article/2367813701f1c55fPharmaRadar360en2026-04-09T18:01:09.000ZUniversity of Oklahomahttps://www.pharmaradar360.com/article/5c16d8f753b89264PharmaRadar360en2026-04-09T17:06:31.000ZISPOR 2026https://www.pharmaradar360.com/article/d06535fc3297cdbbPharmaRadar360en2026-04-09T14:48:36.000ZClinical investigations for medical deviceshttps://www.pharmaradar360.com/article/9b60fcfb9cdcd3c3PharmaRadar360en2026-04-09T14:47:09.000ZDelpharm to attend CDMO Live Europe 2026